Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia

C. C. Chen, C. F. Yang, M. H. Yang, K. D. Lee, W. K. Kwang, J. Y. You, Y. B. Yu, C. H. Ho, C. H. Tzeng, W. K. Chau, H. C. Hsu, J. P. Gau

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Elderly patients with acute myeloid leukemia (AML) generally have an unfavorable clinical course and are under-represented in clinical trials. The aim of this study was to analyze the prognosis and treatment outcome of elderly AML patients. Patients and methods: We studied 205 AML patients aged 65 years or older at our hospital. Prior to study initiation, we designated 13 variables to be analyzed for their impact on complete remission (CR) rate and overall survival (OS). Results: Induction regimen (standard chemotherapy) and good performance status (PS) (Eastern Cooperative Oncology Group PS 0-1) independently influenced the achievement of CR. Multivariate analysis also determined five poor prognostic factors for OS: poor PS (score 2-4), presence of comorbidities, elevated serum lactate dehydrogenase level (≥2× upper normal limit), extreme leukocytosis (≥100 × 109 /l) and marked thrombocytopenia (≤20 × 109/l). Age was not an independent contributing factor in terms of either CR attainment or OS duration. Low-risk patients, who possessed one or less non-leukocytosis poor prognostic factor, had significantly longer disease-free survival and OS than their high-risk counterparts. Conclusions: Elderly AML patients should be risk-stratified at diagnosis. Anthracycline-based induction chemotherapy would be the best therapeutic option for such patients.

Original languageEnglish
Pages (from-to)1366-1373
Number of pages8
JournalAnnals of Oncology
Volume16
Issue number8
DOIs
Publication statusPublished - Aug 2005
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Survival
Induction Chemotherapy
Anthracyclines
Leukocytosis
Thrombocytopenia
Disease-Free Survival
Comorbidity
Multivariate Analysis
Survival Rate
Clinical Trials
Drug Therapy
Serum

Keywords

  • AML
  • Elderly
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. / Chen, C. C.; Yang, C. F.; Yang, M. H.; Lee, K. D.; Kwang, W. K.; You, J. Y.; Yu, Y. B.; Ho, C. H.; Tzeng, C. H.; Chau, W. K.; Hsu, H. C.; Gau, J. P.

In: Annals of Oncology, Vol. 16, No. 8, 08.2005, p. 1366-1373.

Research output: Contribution to journalArticle

Chen, CC, Yang, CF, Yang, MH, Lee, KD, Kwang, WK, You, JY, Yu, YB, Ho, CH, Tzeng, CH, Chau, WK, Hsu, HC & Gau, JP 2005, 'Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia', Annals of Oncology, vol. 16, no. 8, pp. 1366-1373. https://doi.org/10.1093/annonc/mdi259
Chen, C. C. ; Yang, C. F. ; Yang, M. H. ; Lee, K. D. ; Kwang, W. K. ; You, J. Y. ; Yu, Y. B. ; Ho, C. H. ; Tzeng, C. H. ; Chau, W. K. ; Hsu, H. C. ; Gau, J. P. / Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. In: Annals of Oncology. 2005 ; Vol. 16, No. 8. pp. 1366-1373.
@article{37c104f6d3d94f10b9c98fd6882f75a8,
title = "Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia",
abstract = "Background: Elderly patients with acute myeloid leukemia (AML) generally have an unfavorable clinical course and are under-represented in clinical trials. The aim of this study was to analyze the prognosis and treatment outcome of elderly AML patients. Patients and methods: We studied 205 AML patients aged 65 years or older at our hospital. Prior to study initiation, we designated 13 variables to be analyzed for their impact on complete remission (CR) rate and overall survival (OS). Results: Induction regimen (standard chemotherapy) and good performance status (PS) (Eastern Cooperative Oncology Group PS 0-1) independently influenced the achievement of CR. Multivariate analysis also determined five poor prognostic factors for OS: poor PS (score 2-4), presence of comorbidities, elevated serum lactate dehydrogenase level (≥2× upper normal limit), extreme leukocytosis (≥100 × 109 /l) and marked thrombocytopenia (≤20 × 109/l). Age was not an independent contributing factor in terms of either CR attainment or OS duration. Low-risk patients, who possessed one or less non-leukocytosis poor prognostic factor, had significantly longer disease-free survival and OS than their high-risk counterparts. Conclusions: Elderly AML patients should be risk-stratified at diagnosis. Anthracycline-based induction chemotherapy would be the best therapeutic option for such patients.",
keywords = "AML, Elderly, Prognosis, Treatment",
author = "Chen, {C. C.} and Yang, {C. F.} and Yang, {M. H.} and Lee, {K. D.} and Kwang, {W. K.} and You, {J. Y.} and Yu, {Y. B.} and Ho, {C. H.} and Tzeng, {C. H.} and Chau, {W. K.} and Hsu, {H. C.} and Gau, {J. P.}",
year = "2005",
month = "8",
doi = "10.1093/annonc/mdi259",
language = "English",
volume = "16",
pages = "1366--1373",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia

AU - Chen, C. C.

AU - Yang, C. F.

AU - Yang, M. H.

AU - Lee, K. D.

AU - Kwang, W. K.

AU - You, J. Y.

AU - Yu, Y. B.

AU - Ho, C. H.

AU - Tzeng, C. H.

AU - Chau, W. K.

AU - Hsu, H. C.

AU - Gau, J. P.

PY - 2005/8

Y1 - 2005/8

N2 - Background: Elderly patients with acute myeloid leukemia (AML) generally have an unfavorable clinical course and are under-represented in clinical trials. The aim of this study was to analyze the prognosis and treatment outcome of elderly AML patients. Patients and methods: We studied 205 AML patients aged 65 years or older at our hospital. Prior to study initiation, we designated 13 variables to be analyzed for their impact on complete remission (CR) rate and overall survival (OS). Results: Induction regimen (standard chemotherapy) and good performance status (PS) (Eastern Cooperative Oncology Group PS 0-1) independently influenced the achievement of CR. Multivariate analysis also determined five poor prognostic factors for OS: poor PS (score 2-4), presence of comorbidities, elevated serum lactate dehydrogenase level (≥2× upper normal limit), extreme leukocytosis (≥100 × 109 /l) and marked thrombocytopenia (≤20 × 109/l). Age was not an independent contributing factor in terms of either CR attainment or OS duration. Low-risk patients, who possessed one or less non-leukocytosis poor prognostic factor, had significantly longer disease-free survival and OS than their high-risk counterparts. Conclusions: Elderly AML patients should be risk-stratified at diagnosis. Anthracycline-based induction chemotherapy would be the best therapeutic option for such patients.

AB - Background: Elderly patients with acute myeloid leukemia (AML) generally have an unfavorable clinical course and are under-represented in clinical trials. The aim of this study was to analyze the prognosis and treatment outcome of elderly AML patients. Patients and methods: We studied 205 AML patients aged 65 years or older at our hospital. Prior to study initiation, we designated 13 variables to be analyzed for their impact on complete remission (CR) rate and overall survival (OS). Results: Induction regimen (standard chemotherapy) and good performance status (PS) (Eastern Cooperative Oncology Group PS 0-1) independently influenced the achievement of CR. Multivariate analysis also determined five poor prognostic factors for OS: poor PS (score 2-4), presence of comorbidities, elevated serum lactate dehydrogenase level (≥2× upper normal limit), extreme leukocytosis (≥100 × 109 /l) and marked thrombocytopenia (≤20 × 109/l). Age was not an independent contributing factor in terms of either CR attainment or OS duration. Low-risk patients, who possessed one or less non-leukocytosis poor prognostic factor, had significantly longer disease-free survival and OS than their high-risk counterparts. Conclusions: Elderly AML patients should be risk-stratified at diagnosis. Anthracycline-based induction chemotherapy would be the best therapeutic option for such patients.

KW - AML

KW - Elderly

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=23844502627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844502627&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi259

DO - 10.1093/annonc/mdi259

M3 - Article

C2 - 15956039

AN - SCOPUS:23844502627

VL - 16

SP - 1366

EP - 1373

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -